SGSH and mucopolysaccharidosis type 3A: While both injection routes facilitate sulfamidase delivery to central retina, for the first time we demonstrate that i.v. but not intra‐CSF infusions of AAV9‐CMV‐sulfamidase enable treatment of peripheral retina in MPS IIIA, a site distant from the optic nerve.